MAI Capital Management Has $816,000 Stock Holdings in Kenvue Inc. (NYSE:KVUE)

MAI Capital Management trimmed its position in Kenvue Inc. (NYSE:KVUE) by 10.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,292 shares of the company’s stock after selling 3,960 shares during the quarter. MAI Capital Management’s holdings in Kenvue were worth $816,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Leo Wealth LLC grew its position in shares of Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after buying an additional 481 shares during the period. Massmutual Trust Co. FSB ADV raised its position in shares of Kenvue by 6.2% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after acquiring an additional 492 shares during the period. Wolff Wiese Magana LLC boosted its stake in Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after acquiring an additional 501 shares during the last quarter. Marathon Capital Management lifted its stake in Kenvue by 0.3% in the second quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after buying an additional 514 shares in the last quarter. Finally, Poehling Capital Management INC. lifted its position in Kenvue by 0.5% in the 2nd quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock valued at $1,908,000 after acquiring an additional 547 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $24.10 on Friday. The stock has a market capitalization of $46.21 billion, a P/E ratio of 43.24, a price-to-earnings-growth ratio of 2.15 and a beta of 1.36. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm’s fifty day simple moving average is $22.81 and its two-hundred day simple moving average is $20.80. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.24.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter last year, the firm posted $0.31 EPS. The company’s quarterly revenue was down .4% on a year-over-year basis. As a group, analysts predict that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be issued a dividend of $0.205 per share. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.40%. Kenvue’s dividend payout ratio is currently 149.09%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. UBS Group upped their price target on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft lifted their price objective on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Bank of America increased their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Jefferies Financial Group began coverage on Kenvue in a research note on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price for the company. Finally, Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective on the stock. in a report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.